Distributive Shock
7
1
1
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
28.6%
2 terminated out of 7 trials
50.0%
-36.5% vs benchmark
29%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Angiotensin II for Distributive Shock
Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
A Study of LJPC-501 in Pediatric Patients With Hypotension
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Expanded Access for LJPC-501